Abstract Number: 1444 • 2013 ACR/ARHP Annual Meeting
Immunogenicity Induced By Tumor Necrosis Factor Antagonists In Chronic Inflammatory Arthropathies: Retrospective Study In Clinical Practice Conditions
Background/Purpose: Biological therapy has proved efficacious in various chronic inflammatory arthropathies but, in practice, clinical efficacy is reduced in some patients, suggesting drug-induced immunogenicity as…Abstract Number: 491 • 2013 ACR/ARHP Annual Meeting
Infection Risk Among Patients Receiving Concurrent Denosumab and Biologic Or Non-Biologic DMARD Therapy: An Analysis Of The Consortium Of Rheumatology Researchers Of North America (CORRONA) Registry
Background/Purpose: RANKL is a cytokine member of the tumor necrosis family that mediates osteoclastic bone resorption. Denosumab prevents RANKL from activating RANK on the cell…Abstract Number: 2169 • 2013 ACR/ARHP Annual Meeting
Short Term Efficacy Of Biologic Agents In Patients With Systemic Juvenile Idiopathic Arthritis: Network Meta-Analysis Of Randomized Trials
Background/Purpose: Systemic juvenile idiopathic arthritis (SJIA) is a severe subtype of JIA, which includes systemic features such as fever, rash, elevated inflammatory markers along with…Abstract Number: 1451 • 2013 ACR/ARHP Annual Meeting
Comparison Of Clinical Characteristics Of Patients With Rheumatoid Arthritis Receiving Their First Biologic and Biologic-Naïve Patients Considered Biologic-Suitable In The United States
Background/Purpose: Data on clinical status of biologic-naïve Rheumatoid Arthritis (RA) patients who are considered suitable for biologic therapy (by their physicians) is lacking. We assessed…Abstract Number: 462 • 2013 ACR/ARHP Annual Meeting
Reduced Response To Biologic Treatments in Rheumatoid Arthritis Patients Affected By Arterial Hypertension
Background/Purpose: Several reports show that the presence of comorbidities negatively influences both functional status (1) and quality of life (2) in rheumatoid arthritis (RA). No…Abstract Number: 2056 • 2013 ACR/ARHP Annual Meeting
Use Of Biologics In Polymyositis and Dermatomyositis – A National Register Study
Background/Purpose: Biologics have been used off-label in treatment of refractory polymyositis (PM) and dermatomyositis (DM). In this study we aimed to describe the use of…Abstract Number: 1419 • 2013 ACR/ARHP Annual Meeting
Mode Of Action Change Not Necessary After Failing The First Tumornecrosisfactor Inhibitor: Preliminary Results Of a Randomized Controlled Trial
Background/Purpose: The best treatment option after a patient has failed a first TNFi is still unknown. Therefore the objective of this randomized open label study…Abstract Number: 448 • 2013 ACR/ARHP Annual Meeting
Effectiveness Of Tocilizumab In Monotherapy and In Combination With Different Synthetic Dmards: A Registry-Based Comparison Study
Background/Purpose: Tocilizumab (TCZ) is efficacious in monotherapy and in combination with methotrexate (MTX) or other DMARDs. However, longitudinal data from large registry populations are missing.…Abstract Number: 2036 • 2013 ACR/ARHP Annual Meeting
Biologic Therapy For Relapsing Polychondritis: Old and New Efficacy Indices
Background/Purpose: The inflammatory milieu in affected tissues from Relapsing Polychondritis (RP) is rich in TNF-α, IL-1-β and IL-6. Cytokine-targeted biologic therapies has therefore been proposed…Abstract Number: 1420 • 2013 ACR/ARHP Annual Meeting
Induction Therapy With Adalimumab On Top Of An Aggressive Treat-To-Target Strategy With Methotrexate and Intraarticular Corticosteroid Reduces Radiographic Erosive Progression In Early Rheumatoid Arthritis, Even After Withdrawal Of Adalimumab. Results Of a 2-Year Trial (OPERA)
Background/Purpose: In a randomized double-blind, placebo-controlled 2-year investigator-initiated trial of patients with early rheumatoid arthritis¹ (RA) we aimed to investigate if additional adalimumab (ADA) for…Abstract Number: 453 • 2013 ACR/ARHP Annual Meeting
Impact Of Inadequate Adherence On Clinical Outcomes: Results From The Biologics In Rheumatoid Arthritis Genetics and Genomics Study Syndicate Cohort
Background/Purpose: Biologic therapy has revolutionised patient prognosis in rheumatoid arthritis (RA). In the UK, continuing biologic therapy requires a sustained response as determined by the…Abstract Number: 2841 • 2013 ACR/ARHP Annual Meeting
Inflammation and Structural Progression In The Sacroiliac Joints Of Patients With Axial Spa Treated With Adalimumab Or Placebo As Assessed By The Berlin and The Spondyloarthritis Research Consortium Of Canada MRI Methods
Background/Purpose: To investigate changes in inflammation and structural progression in the sacroiliac joints (SIJs) in patients with axial spondyloarthritis (SpA) during treatment with adalimumab and…Abstract Number: 2013 • 2013 ACR/ARHP Annual Meeting
Biologic Therapy In Refractory Uveitis Of Sarcoidosis. Multicenter Study Of 16 Patients
Background/Purpose: Uveitis related to sarcoidosis is a potentially severe complication. Corticosteroids are the first line of treatment. In refractory cases or in those with unacceptable…Abstract Number: 1425 • 2013 ACR/ARHP Annual Meeting
Discontinuation Of Tumor Necrosis Factor Inhibitors In Rheumatoid Arthritis Patients In Low Disease Activity: Persistent Benefits
Background/Purpose: A key question is whether biologic agents can be stopped but clinical benefit maintained for rheumatoid arthritis (RA) patients (pts) in remission or low…Abstract Number: 432 • 2013 ACR/ARHP Annual Meeting
Use Of Rituximab As Second Line Biologic Agent Compared With Adalimumab, Etanercept and Infliximab In Patients With Rheumatoid Arthritis. a Report From The Rhumadata® Clinical Database and Registry
Background/Purpose: The order of use of biologic agents after failing a TNF inhibitor is still a question for debate. Phase III trial data in TNF-IR…
ACR Meeting Abstracts